Skip to Main Content
our new site.
NLM Technical Bulletin
Full Text View
No Study Results Posted
DE-111 Against Tafluprost Ophthalmic Solution 0.0015% Alone and Concomitant Use of Tafluprost Ophthalmic Solution 0.0015% Plus Timolol Ophthalmic Solution 0.5%
This study has been completed.
Study NCT01342081 Information provided by Santen Pharmaceutical Co., Ltd.
First Received on April 25, 2011. Last Updated on July 26, 2012
History of Changes
Related Studies can be found by searching for the Conditions, Interventions, and Sponsors found in this study:
Conditions listed in this trial
Open Angle Glaucoma
Additional conditions recognized in this trial
More general conditions related to this trial
Interventions listed in this trial
DE-111 ophthalmic solution
Additional drug interventions recognized in this trial
More general drug interventions related to this trial
Molecular Mechanisms of Pharmacological Action
Physiological Effects of Drugs
Sponsors listed in this trial
Santen Pharmaceutical Co., Ltd.
Back to top of Main Content
Contact Help Desk
Lister Hill National Center for Biomedical Communications
U.S. National Library of Medicine
U.S. National Institutes of Health
U.S. Department of Health & Human Services
Freedom of Information Act
Links to all studies - primarily for crawlers